GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma
Stopped It did not show a significant benefit to justify completing the full target accrual.
Conditions
- Hodgkin's Lymphoma - Relapsed/Refractory
- Non-Hodgkin's Lymphoma - Aggressive
- Follicular Lymphoma
Interventions
- DRUG: Gemcitabine
- DRUG: Melphalan
- OTHER: ASCT
Sponsor
AHS Cancer Control Alberta
Collaborators